It may not get the attention as often as larger-cap biotech stocks like Celgene Corp. (NASDAQ: CELG) and Gilead Sciences (NASDAQ: GILD), but a bunch of recent drug approvals could soon change that for Regeneron Pharmaceuticals (NASDAQ: REGN). Is Regeneron Pharmaceuticals about to reward investors with a steady stream of big-time sales and profit growth?